首页> 外文OA文献 >PND3 Indirect Treatment Comparison (ITC) Analysis of Therapies That are Often Considered for Treatment-Experienced Patients With Relapsing-Remitting Multiple Sclerosis

【2h】

PND3 Indirect Treatment Comparison (ITC) Analysis of Therapies That are Often Considered for Treatment-Experienced Patients With Relapsing-Remitting Multiple Sclerosis

机译：PND3间接治疗比较（ITC）对经验丰富的复发-缓解型多发性硬化症患者通常考虑的治疗方法的分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Allen F.L.; Osei-assibey G.; Arnold R.; Deniz B.;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches [J] . Berardi Andrea, Siddiqui Mohd Kashif, Treharne Catrin, Current medical research and opinion . 2019,第8期

机译：估计克拉酮片剂与替代疾病修饰治疗的对比疗效在活性复发型多发性硬化症中：使用元回归调整患者特征和匹配调整的间接治疗比较方法
2. No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis [J] . Nixon Richard, Bergvall Niklas, Tomic Davorka, Advances in therapy. . 2014,第11期

机译：没有疾病活动的证据：口服疗法治疗复发性多发性硬化症的间接比较
3. Immunomodulatory therapy in 5798 relapsing-remitting multiple sclerosis (RRMS) patients over time under special consideration of switching to oral DMD: A retrospective data analysis [J] . A. Bergmann, T. Ziemssen, S. Braune Journal of the Neurological Sciences: Official Bulletin of the World Federation of Neurology . 2017,第期

机译：5798年的免疫调节治疗在特殊考虑到口服DMD的特殊考虑时重复延迟多发性硬化症（RRMS）患者：回顾性数据分析
4. GPU Accelerated Analysis of Treg-Teff Cross Regulation in Relapsing-Remitting Multiple Sclerosis [C] . Marco Beccuti, Paolo Cazzaniga, Marzio Pennisi, International Conference on Parallel and Distributed Computing . 2019

机译：GPU在复发延迟多发性硬化中的Treg-Teff交叉调节的分析
5. Cost-Effectiveness of Oral Agents in Relapsing-Remitting Multiple Sclerosis Compared to Interferon-Based Therapy in Saudi Arabia [D] . Alskaabi, May. 2017

机译：沙特阿拉伯口服药物在复发缓解型多发性硬化症中的成本效果与基于干扰素的疗法相比
6. The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials [O] . Georgios Tsivgoulis, Aristeidis H. Katsanos, Dimitris Mavridis, -1

机译：纳他珠单抗与芬戈莫德治疗复发缓解型多发性硬化症的疗效：系统评价随机安慰剂对照试验的间接证据和观察性头对头试验的荟萃分析。
7. Immunomodulatory therapy in 6427 relapsing-remitting multiple sclerosis (RRMS) patients over time under special consideration of switching to oral DMD: A retrospective data analysis [O] . A. Bergmann, K.H. Goesswein, S. Braune 2019

机译：6427中的免疫调节治疗在特殊考虑到口服DMD的特殊考虑时重复延迟多发性硬化症（RRMS）患者：回顾性数据分析

PND3 Indirect Treatment Comparison (ITC) Analysis of Therapies That are Often Considered for Treatment-Experienced Patients With Relapsing-Remitting Multiple Sclerosis

著录项

相似文献

相关主题

期刊订阅